Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Fiche publication
Date publication
mai 2022
Journal
Tumori
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BASTOGNE Thierry, Dr MIRJOLET Céline
Tous les auteurs :
Deneuve S, Bastogne T, Duclos M, Mirjolet C, Bois P, Bachmann P, Nokovitch L, Roux PE, Girodet D, Poupart M, Zrounba P, Claude L, Ferella L, Iacovelli NA, Foray N, Rancati T, Pereira S
Lien Pubmed
Résumé
Radiotherapy (RT) against head and neck squamous cell carcinomas (HNSCC) may lead to severe toxicity in 30-40% of patients. The normal tissue complication probability (NTCP) models, based on dosimetric data refined the normal tissue dose/volume tolerance guidelines. In parallel, the radiation-induced nucleoshuttling (RIANS) of the Ataxia-Telangiectasia Mutated protein (pATM) is a predictive approach of individual intrinsic radiosensitivity. Here, we combined NTCP with RADIODTECT©, a blood assay derived from the RIANS model, to predict RT toxicity in HNSCC patients.
Mots clés
Head and neck squamous cell carcinomas, biological marker, normal tissue complication probability, pATM, predictive models, radiation-induced toxicity
Référence
Tumori. 2022 05 16;:3008916221078061